STAAR Surgical price target raised to $55 from $43 at Canaccord

Canaccord analyst Jason Mills raised his price target to $55 from $43 following the FDA approval of its Toric ICL. The analyst said it represent tangible progress for the company along the path of tapping into the U.S. refractive market and could also serve as upside to current guidance. Mills reiterated his Buy rating on STAAR Surgical shares.
https://thefly.com/landingPageNews.php?id=2790541